ABIONYX Pharma S.A.
PAR: ABNX.PA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Euronext Paris
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Sir Cyrille Tupin
- Employees
- 51
- Headquarters
- Balma, France
- IPO year
- 2015
- Market cap
- €125.0M
- Website
- https://abionyx.com
Loading ABNX…
Loading profile data…Frequently asked questions about ABNX
What does ABIONYX Pharma S.A. (ABNX.PA) do?
ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. The company is developing CER-001, a negatively-charged lipoprotein particle which contains human recombinant apoA-I, the natural high density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylgly...
Where does ABNX.PA trade?
ABIONYX Pharma S.A. (ABNX.PA) trades on the Euronext Paris.
What sector is ABNX.PA in?
ABIONYX Pharma S.A. (ABNX.PA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of ABIONYX Pharma S.A.?
Sir Cyrille Tupin is the chief executive officer of ABIONYX Pharma S.A. (ABNX.PA).
Where is ABIONYX Pharma S.A. headquartered?
ABIONYX Pharma S.A. is headquartered in France.
Does ABNX.PA pay a dividend?
ABIONYX Pharma S.A. (ABNX.PA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ABNX.PA go public?
ABIONYX Pharma S.A. (ABNX.PA) completed its initial public offering in 2015.